 | • レポートコード：QAF27614 • 出版社/出版日：QYResearch / 2021年3月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、144ページ • 納品方法：Eメール（即日納品） • 産業分類：医薬品 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本市場調査資料では、世界の化学療法誘発性末梢神経障害治療市場について種類別（カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他）、用途別（プラチナ剤、タキサン、ビンカアルカロイド、その他）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・化学療法誘発性末梢神経障害治療市場の概要 ・世界の主要地域別化学療法誘発性末梢神経障害治療市場規模2016-2027 ・主要プレイヤーの競争状況・市場シェア ・世界の化学療法誘発性末梢神経障害治療市場規模2016-2021：種類別（カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他） ・世界の化学療法誘発性末梢神経障害治療市場予測2012-2027：種類別（カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他） ・世界の化学療法誘発性末梢神経障害治療市場規模2016-2021：用途別（プラチナ剤、タキサン、ビンカアルカロイド、その他） ・世界の化学療法誘発性末梢神経障害治療市場予測2012-2027：用途別（プラチナ剤、タキサン、ビンカアルカロイド、その他） ・化学療法誘発性末梢神経障害治療のアメリカ市場規模と予測2016-2021 ・化学療法誘発性末梢神経障害治療のヨーロッパ市場規模と予測2016-2021 ・化学療法誘発性末梢神経障害治療の中国市場規模と予測2016-2021 ・化学療法誘発性末梢神経障害治療の日本市場規模と予測2016-2021 ・化学療法誘発性末梢神経障害治療の東南アジア市場規模と予測2016-2021 ・化学療法誘発性末梢神経障害治療のインド市場規模と予測2016-2021 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Aptinyx Inc、Asahi Kasei Pharma Corp、Regenacy Pharmaceuticals、MAKScientific LLC、Metys Pharmaceuticals AG、Nemus Bioscience Inc、PledPharma、Sova Pharmaceuticals Inc、DermaXon LLC、Kineta Inc、Krenitsky Pharmaceuticals Inc、PeriphaGen、Apexian Pharma、WinSanTor、Solasia Pharma K.K.） ・化学療法誘発性末梢神経障害治療の製造コスト分析 ・販売チャネル、流通業者、顧客 ・化学療法誘発性末梢神経障害治療の市場動向・機会・課題 ・調査の結論 |
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
By region, the United States has the highest share of income, reaching 47.25 percent in 2019.
Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market
The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at US$ 1669.5 in 2020 and will reach US$ 2422.3 million by the end of 2027, growing at a CAGR of 6.4% during 2022-2027.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Market Size
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Segment by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
The Chemotherapy Induced Peripheral Neuropathy Treatment market is analysed and market size information is provided by regions (countries). Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Solasia Pharma K.K.
1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Scope
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016 & 2021 & 2027)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts (2016-2027)
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends (2016-2027)
2 Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Forecasts by Region
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)
2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2021)
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.6 India Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Competition Landscape by Players
3.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Sales (2016-2021)
3.2 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2016-2021)
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2020)
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (2016-2021)
3.5 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Type (2016-2021)
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2016-2021)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2022-2027)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2022-2027)
4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2022-2027)
5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Application (2016-2021)
5.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
5.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)
5.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2016-2021)
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2022-2027)
5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2022-2027)
5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2022-2027)
6 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
6.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
6.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
6.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
6.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2016-2021)
6.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2022-2027)
7 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
7.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
7.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
7.3.1 Europe 144 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 144 Sales Breakdown by Application (2022-2027)
8 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
8.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
8.1.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
8.1.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
8.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
8.2.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
8.2.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
8.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
8.3.1 China 313 Sales Breakdown by Application (2016-2021)
8.3.2 China 313 Sales Breakdown by Application (2022-2027)
9 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
9.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
9.1.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
9.1.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
9.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
9.2.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
9.2.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
9.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
10.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
10.1.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
10.1.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
10.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
10.2.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)
11 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
11.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
11.1.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
11.1.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
11.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
11.2.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
11.2.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
11.3 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
11.3.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2016-2021)
11.3.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Chemotherapy Induced Peripheral Neuropathy Treatment Business
12.1 Aptinyx Inc
12.1.1 Aptinyx Inc Corporation Information
12.1.2 Aptinyx Inc Business Overview
12.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.1.5 Aptinyx Inc Recent Development
12.2 Asahi Kasei Pharma Corp
12.2.1 Asahi Kasei Pharma Corp Corporation Information
12.2.2 Asahi Kasei Pharma Corp Business Overview
12.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.2.5 Asahi Kasei Pharma Corp Recent Development
12.3 Regenacy Pharmaceuticals
12.3.1 Regenacy Pharmaceuticals Corporation Information
12.3.2 Regenacy Pharmaceuticals Business Overview
12.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.3.5 Regenacy Pharmaceuticals Recent Development
12.4 MAKScientific LLC
12.4.1 MAKScientific LLC Corporation Information
12.4.2 MAKScientific LLC Business Overview
12.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.4.5 MAKScientific LLC Recent Development
12.5 Metys Pharmaceuticals AG
12.5.1 Metys Pharmaceuticals AG Corporation Information
12.5.2 Metys Pharmaceuticals AG Business Overview
12.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.5.5 Metys Pharmaceuticals AG Recent Development
12.6 Nemus Bioscience Inc
12.6.1 Nemus Bioscience Inc Corporation Information
12.6.2 Nemus Bioscience Inc Business Overview
12.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.6.5 Nemus Bioscience Inc Recent Development
12.7 PledPharma
12.7.1 PledPharma Corporation Information
12.7.2 PledPharma Business Overview
12.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.7.5 PledPharma Recent Development
12.8 Sova Pharmaceuticals Inc
12.8.1 Sova Pharmaceuticals Inc Corporation Information
12.8.2 Sova Pharmaceuticals Inc Business Overview
12.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.8.5 Sova Pharmaceuticals Inc Recent Development
12.9 DermaXon LLC
12.9.1 DermaXon LLC Corporation Information
12.9.2 DermaXon LLC Business Overview
12.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.9.5 DermaXon LLC Recent Development
12.10 Kineta Inc
12.10.1 Kineta Inc Corporation Information
12.10.2 Kineta Inc Business Overview
12.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.10.5 Kineta Inc Recent Development
12.11 Krenitsky Pharmaceuticals Inc
12.11.1 Krenitsky Pharmaceuticals Inc Corporation Information
12.11.2 Krenitsky Pharmaceuticals Inc Business Overview
12.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.11.5 Krenitsky Pharmaceuticals Inc Recent Development
12.12 PeriphaGen
12.12.1 PeriphaGen Corporation Information
12.12.2 PeriphaGen Business Overview
12.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.12.5 PeriphaGen Recent Development
12.13 Apexian Pharma
12.13.1 Apexian Pharma Corporation Information
12.13.2 Apexian Pharma Business Overview
12.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.13.5 Apexian Pharma Recent Development
12.14 WinSanTor
12.14.1 WinSanTor Corporation Information
12.14.2 WinSanTor Business Overview
12.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.14.5 WinSanTor Recent Development
12.15 Solasia Pharma K.K.
12.15.1 Solasia Pharma K.K. Corporation Information
12.15.2 Solasia Pharma K.K. Business Overview
12.15.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.15.5 Solasia Pharma K.K. Recent Development
13 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
13.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
13.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
14.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
15 Market Dynamics
15.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
15.2 Chemotherapy Induced Peripheral Neuropathy Treatment Drivers
15.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
15.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Region (2016-2021)
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Region (2016-2021)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share Forecast by Region (2022-2027)
Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) of Key Companies (2016-2021)
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2016-2021)
Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2016-2021)
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2020)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit) of Key Company (2016-2021)
Table 18. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites and Area Served
Table 19. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2016-2021)
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2016-2021)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Type (2016-2021)
Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2022-2027)
Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2022-2027)
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Type (2022-2027)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2016-2021)
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2016-2021)
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Application (2016-2021)
Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2022-2027)
Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2022-2027)
Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2022-2027)
Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Application (2022-2027)
Table 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2016-2021)
Table 39. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2016-2021)
Table 40. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2016-2021)
Table 42. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)
Table 43. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 44. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2022-2027) & (K Units)
Table 45. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2022-2027)
Table 46. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)
Table 47. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 48. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2022-2027) & (K Units)
Table 49. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2022-2027)
Table 50. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2016-2021)
Table 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2016-2021)
Table 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2016-2021)
Table 54. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)
Table 55. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 56. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2022-2027) & (K Units)
Table 57. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2022-2027)
Table 58. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)
Table 59. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 60. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2022-2027) & (K Units)
Table 61. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2022-2027)
Table 62. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2016-2021)
Table 63. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2016-2021)
Table 64. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2016-2021)
Table 66. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)
Table 67. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 68. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2022-2027) & (K Units)
Table 69. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2022-2027)
Table 70. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)
Table 71. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 72. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2022-2027) & (K Units)
Table 73. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2022-2027)
Table 74. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2016-2021)
Table 75. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2016-2021)
Table 76. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2016-2021)
Table 78. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)
Table 79. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 80. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2022-2027) & (K Units)
Table 81. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2022-2027)
Table 82. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)
Table 83. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 84. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2022-2027) & (K Units)
Table 85. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2022-2027)
Table 98. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2016-2021)
Table 99. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2016-2021)
Table 100. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2016-2021)
Table 102. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016-2021) & (K Units)
Table 103. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
Table 104. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2022-2027) & (K Units)
Table 105. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2022-2027)
Table 106. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2016-2021) & (K Units)
Table 107. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
Table 108. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2022-2027) & (K Units)
Table 109. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2022-2027)
Table 110. Aptinyx Inc Corporation Information
Table 111. Aptinyx Inc Description and Business Overview
Table 112. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 113. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 114. Aptinyx Inc Recent Development
Table 115. Asahi Kasei Pharma Corp Corporation Information
Table 116. Asahi Kasei Pharma Corp Description and Business Overview
Table 117. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 118. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 119. Asahi Kasei Pharma Corp Recent Development
Table 120. Regenacy Pharmaceuticals Corporation Information
Table 121. Regenacy Pharmaceuticals Description and Business Overview
Table 122. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 123. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 124. Regenacy Pharmaceuticals Recent Development
Table 125. MAKScientific LLC Corporation Information
Table 126. MAKScientific LLC Description and Business Overview
Table 127. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 128. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 129. MAKScientific LLC Recent Development
Table 130. Metys Pharmaceuticals AG Corporation Information
Table 131. Metys Pharmaceuticals AG Description and Business Overview
Table 132. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 133. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 134. Metys Pharmaceuticals AG Recent Development
Table 135. Nemus Bioscience Inc Corporation Information
Table 136. Nemus Bioscience Inc Description and Business Overview
Table 137. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 138. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 139. Nemus Bioscience Inc Recent Development
Table 140. PledPharma Corporation Information
Table 141. PledPharma Description and Business Overview
Table 142. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 143. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 144. PledPharma Recent Development
Table 145. Sova Pharmaceuticals Inc Corporation Information
Table 146. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 147. Sova Pharmaceuticals Inc Description and Business Overview
Table 148. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 149. Sova Pharmaceuticals Inc Recent Development
Table 150. DermaXon LLC Corporation Information
Table 151. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 152. DermaXon LLC Description and Business Overview
Table 153. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 154. DermaXon LLC Recent Development
Table 155. Kineta Inc Corporation Information
Table 156. Kineta Inc Description and Business Overview
Table 157. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 158. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 159. Kineta Inc Recent Development
Table 160. Krenitsky Pharmaceuticals Inc Corporation Information
Table 161. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 162. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 163. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 164. Krenitsky Pharmaceuticals Inc Recent Development
Table 165. PeriphaGen Corporation Information
Table 166. PeriphaGen Description and Business Overview
Table 167. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 168. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 169. PeriphaGen Recent Development
Table 170. Apexian Pharma Corporation Information
Table 171. Apexian Pharma Description and Business Overview
Table 172. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 173. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 174. Apexian Pharma Recent Development
Table 175. WinSanTor Corporation Information
Table 176. WinSanTor Description and Business Overview
Table 177. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 178. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 179. WinSanTor Recent Development
Table 180. Solasia Pharma K.K. Corporation Information
Table 181. Solasia Pharma K.K. Description and Business Overview
Table 182. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 183. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 184. Solasia Pharma K.K. Recent Development
Table 185. Production Base and Market Concentration Rate of Raw Material
Table 186. Key Suppliers of Raw Materials
Table 187. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 188. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table 189. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 190. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Table 191. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 192. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 193. Research Programs/Design for This Report
Table 194. Key Data Information from Secondary Sources
Table 195. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2021 & 2027
Figure 6. Platinum Agents Examples
Figure 7. Taxanes Examples
Figure 8. Vinca Alkaloids Examples
Figure 9. Others Examples
Figure 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2016-2027) & (US$ Million)
Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2016-2027)
Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends Growth Rate (2016-2027) (US$/Unit)
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2016 VS 2021
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2021 VS 2027
Figure 16. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2016-2027)
Figure 17. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2016-2027)
Figure 18. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2016-2027)
Figure 19. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2016-2027)
Figure 20. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2016-2027)
Figure 21. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) and Growth Rate (2016-2027)
Figure 22. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2016-2027)
Figure 23. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2016-2027)
Figure 24. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2016-2027)
Figure 25. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2016-2027)
Figure 26. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2016-2027)
Figure 27. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2016-2027)
Figure 28. Global 5 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment: 2016 & 2020
Figure 29. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2016-2021)
Figure 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate by Type in 2016 & 2020
Figure 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2016-2021)
Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate by Application in 2016 & 2020
Figure 34. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020
Figure 35. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020
Figure 36. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020
Figure 37. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020
Figure 38. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020
Figure 39. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020
Figure 40. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020
Figure 41. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020
Figure 42. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020
Figure 43. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020
Figure 44. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020
Figure 45. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2020
Figure 46. Key Raw Materials Price Trend
Figure 47. Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 48. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 49. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
世界の末梢神経炎治療市場規模・現状・予測（2021年-2027年） Peripheral neuropathy is a syndrome caused by sensory loss, muscle weakness and atrophy, decreased tendon reflexes, and vasomotor symptoms, alone or in any combination. Of all the options for the treatment of peripheral neuritis, analgesics and local anesthetics are the first line of treatment to re…- 世界の化学療法誘発性血小板減少症治療薬市場規模・現状・予測（2021年-2027年） Chemotherapy is the cancer treatment given to patients with different forms of the cancer. Various drugs such as alkylating agents, antimetabolites, targeted therapy, immunotherapy drugs, etc. are used for the cancer treatment. These chemotherapy agents acts against the cancerous as well as normal c…
- 化学療法誘発性悪心・嘔吐（CINV）治療薬のグローバル市場2021 Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs …
- 化学療法による好中球減少薬のグローバル市場調査 2019年 The global Chemotherapy Induced Neutropenia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Chemotherapy Induced Neutropenia Drug volume and value at global level, regional level and company le…
- 世界のオピオイド誘発性副作用治療市場規模・現状・予測（2021年-2027年） Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body a…